Journal
LEUKEMIA
Volume 31, Issue 1, Pages 136-142Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2016.229
Keywords
-
Categories
Funding
- NIH [CA05826]
- FDA [R01-002174]
- Celgene
- Millennium Pharmaceuticals
- Amyloidosis Research Fund
- Werner and Elaine Dannheiser Fund for Research on the Biology of Aging of the Lymphoma Foundation
- Memorial Sloan Kettering P30 NCI Cancer Center Support Grant (CCSG) [P30 CA008748]
- Thomas Israel Foundation
Ask authors/readers for more resources
Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
